Evogene logo

Evogene(EVGN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.37
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for EVGN

11/13/2026: EVGN (1-star) is currently NOT-A-BUY. Pass it for now.

Evogene is a micro-cap computational biology and chemistry company that applies artificial intelligence to discover life-science products in agriculture and human health. Its primary strengths lie in its proprietary ChemPass AI platform and strategic partnerships with major industry players. The core investment opportunity centers on potential licensing breakthroughs and pipeline milestones from its AI discovery engines. However, investors face significant risks including persistent net losses, negative cash flows, micro-cap volatility, and intense sector competition. The stock is best suited for speculative growth investors willing to monitor partnership updates and cash burn closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitEvogene offers exposure to cutting-edge AI life sciences, but its small revenue scale presents execution uncertainty.
Momentum investorStrong fit while signal remains positiveLow share price and micro-cap status can occasionally spark sharp speculative rallies upon partnership announcements.
Value investorWeak fitPersistent net losses and negative cash flows make traditional fundamental value assessment challenging.
Dividend investorWeak fitThe company does not pay dividends and retains all capital for R&D.
Low-risk investorWeak fitHigh price volatility, regulatory risks, and micro-cap liquidity make it unsuitable for conservative portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighAs a micro-cap stock, small changes in sentiment or news can lead to dramatic price swings.
Valuation riskMedium / highValuation relies heavily on speculative potential of early-stage platform technologies rather than current earnings.
Competition risk (AI and biotech discovery competition)HighThe company competes with numerous well-funded entities applying AI to drug and agricultural discovery.
Business qualityMediumAdvanced technology is offset by early commercial maturity and historical unprofitability.
Dividend incomeLow / noneNo payouts are offered, meaning total return depends entirely on capital appreciation.
Execution riskHighSuccess depends on translating computational predictions into validated commercial products via partners or clinical trials.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 6.70M USD
Price to earnings Ratio -
1Y Target Price 2.15
Price to earnings Ratio -
1Y Target Price 2.15
Volume (30-day avg) 441.0K shares
Beta 0.67
52 Weeks Range 0.25 - 1.26
Updated Date 11/15/2026
52 Weeks Range 0.25 - 1.26
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.55

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -40.79%
Avg. Invested days 19
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
EVGN receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
EVGN has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+48.5%) is partially offset by weak cash generation (FCF margin -353.9%), negative revenue growth (-30.9%), weak profitability (net margin -220.2%).

Financial Health Rating

★★★★★
EVGN's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 60.8%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is EVGN's strongest growth driver at +48.5% FY2025 versus FY2024 (strong, 5 stars). By comparison, free-cash-flow growth (+32.9%, solid) is also solid, while revenue growth (-30.9%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 4.9% and approximately 68.6% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 24.39% supports management-shareholder alignment.

Top 5 Institutional Investors

HRT FINANCIAL LLC 0.68%
Susquehanna International Group, LLP 0.51%
Citadel Advisors Llc 0.32%
XTX Topco Ltd 0.12%
UBS Group AG 0.07%

Unit Economics (Per $1K Revenue)

★★★★★
EVGN generates approximately $-63 of gross profit, $-3,642 of operating income, and $-3,539 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 37.14%

Quantitative Style Profile

★★★★★
EVGN has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Partnerships and CollaborationsUpfront payments, research funding, and milestone/royalty fees from commercial partners utilizing Evogene's tech platforms.Revenue is lumpy and depends heavily on signing and advancing agreements with larger industry players.
Product Development and LicensingDirect commercialization or out-licensing of proprietary seed traits, ag-biologicals, and therapeutic assets.Long-term upside relies on internal assets successfully reaching commercial markets.

Valuation

Trailing PE -
Forward PE -
Enterprise Value -2.37M
Price to Sales(TTM) 4.04
Enterprise Value -2.37M
Price to Sales(TTM) 4.04
Enterprise Value to Revenue 0.23
Enterprise Value to EBITDA -0.81
Shares Outstanding 18.05M
Shares Floating 12.38M
Shares Outstanding 18.05M
Shares Floating 12.38M
Percent Insiders 24.39
Percent Institutions 4.93

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.